EGFR and neoplasm: Similar to murine CRC in vivo, there was no statistically significant difference in tumor growth of human CRC treated with anti-EGFR compared to BATs (Fig. 6A), as would be expected in an EGFR+ colon cancer with intact downstream signaling.